Humoral response 24 months after the first COVID-19 vaccination in people with HIV with and without diabetes

Louise Bering,Line Dam Heftdal,Safura-Luise Heidari,Sebastian Rask Hamm,Cecillie Bo Hansen,Dina Leth Møller,Mia Pries-Heje,Kamille Fogh,Rasmus Bo Hasselbalch,Laura Pérez-Alós,Jan Gerstoft,Thomas Benfield,Selina Kikkenborg Berg,Anne Vinggaard Christensen,Nina Marie Birk,Linda Maria Hilsted,Sisse Rye Ostrowski,Ruth Frikke-Schmidt,Erik Sørensen,Kirsten Grønbæk,Henning Bundgaard,Kasper Iversen,Peter Garred,Susanne Dam Nielsen
DOI: https://doi.org/10.1097/qad.0000000000004026
IF: 4.632
2024-11-18
AIDS
Abstract:People with HIV (PWH) and people with diabetes mellitus have increased risk of severe COVID-19, but little is known about humoral response to COVID-19 vaccines in PWH with DM. We investigated SARS-CoV-2 antireceptor-binding domain (anti-RBD) immunoglobulin G (IgG) geometrical concentrations and neutralizing antibody capacity (nAB) in PWH with and without diabetes mellitus. Anti-RBD IgG and nAB in COVID-19-vaccinated PWH were not associated with diabetes mellitus-status or HbA1c 24 months after the initial COVID-19 vaccination.
immunology,infectious diseases,virology
What problem does this paper attempt to address?